Avelas Biosciences has dosed the first patient in the Period 2 of a Phase ll clinical trial that aims to evaluate AVB-620 for the treatment of women with primary, non-recurrent breast cancer undergoing surgery.

The multi-centre, open-label, single-arm Phase ll trial comprises two separate trial periods.

The Period 1 trial was completed in December last year with the enrolment of 31 patients, who were analysed for optimal conditions to achieve differentiation between malignant and non-malignant tissue using fluorescent signals.

Period 2 is expected to enrol around 108 additional patients to evaluate the ability of AVB-620 to identify malignant tissue at or close to the surface of excised tissue and of tissue that would otherwise have been left behind.

The trial’s primary objective is to determine the accuracy of AVB-620 imaging data to distinguish between malignant and non-malignant tissues over a period of one month.

“We believe that AVB-620 has the potential to significantly reduce the number of breast cancer re-operations.”

The trial’s secondary objectives are safety, identification of malignant tissue types, and evaluation of the timing of avb-620 administration on optical fluorescence characteristics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Avelas Biosciences chief medical officer Steven Chen said: “A technology like AVB-620 has the potential to revolutionise cancer surgery by enabling surgeons to visualise cancer while still in the operating room, and make informed, real-time decisions to improve surgical treatment.

“We believe that AVB-620 has the potential to significantly reduce the number of breast cancer re-operations, which would result in better outcomes for patients and substantial cost savings for healthcare payers.”

AVB-620 is an investigational synthetic protease-activated peptide dye conjugate designed to administer intravenously for the fluorescence detection and localisation of potentially malignant tissue in primary tumour, tumour margins, or lymph nodes.